argenx SEARGX -0.17%80 PB Ratio is 7.49 as of Jun. 27, 2026, which is 17% above its 10-year median of 6.42. GuruFocus rates ARGX with a GF Score™ of 80/100 and a GF Value™ of $1,363.68 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 1,232 Biotechnology companies, argenx SE ranks worse than 81.9% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-27), argenx SE's share price is $885.80. argenx SE's Book Value per Share for the quarter that ended in Mar. 2026 was $118.34. Hence, argenx SE's PB Ratio of today is 7.49.
Warning Sign:
argenx SE stock PB Ratio (=7.76) is close to 2-year high of 7.76.
The historical rank and industry rank for argenx SE's PB Ratio or its related term are showing as below:
ARGX'
s PB Ratio Range Over the Past 10 Years
Min: 3.02 Med: 6.42 Max: 10.43
Current: 7.76
During the past 13 years, argenx SE's highest PB Ratio was 10.43. The lowest was 3.02. And the median was 6.42.
ARGX's PB Ratio is ranked worse than 81.9% of 1232
companies
in the Biotechnology industry
Industry Median: 2.8
vs ARGX: 7.76
During the past 12 months, argenx SE's average Book Value Per Share Growth Rate was 16.90% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 28.20% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 27.90% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 44.10% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of argenx SE was 99.30% per year. The lowest was 24.50% per year. And the median was 38.60% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
argenx SE PB Ratio Related Terms
argenx SE PB Ratio Historical Data
* Premium members only.
The historical data trend for argenx SE's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, argenx SE's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
argenx SE PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, argenx SE's PB Ratio distribution charts can be found below:
* The bar in red indicates where argenx SE's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
argenx SE's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
argenx SE (ARGX) has a PB Ratio of 7.49 as of Jun. 27, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on argenx SE and its competitors. This is 17% above median its historical median of 6.42. Over the past decade, argenx SE's PB Ratio has ranged from 3.02 to 10.43. According to the industry distribution chart, argenx SE ranks #1009 out of 1232 companies in the Biotechnology industry, placing it in the top 81.9%.
Is argenx SE's PB Ratio too high?
argenx SE's current PB Ratio of 7.49 is 17% above median its 10-year median of 6.42. Over the past 10 years, this metric has ranged from a low of 3.02 to a high of 10.43. The Biotechnology industry median PB Ratio is 2.80. argenx SE's value of 7.49 is 167.5% above this industry median. Based on the distribution chart, argenx SE ranks #1009 out of 1232 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, argenx SE has a GF Score™ of 80/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does argenx SE's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, argenx SE ranks #1009 out of 1232 companies for PB Ratio. This places argenx SE in the lower half of its industry. The industry median PB Ratio is 2.80. argenx SE's value of 7.49 is 167.5% above this benchmark. Historically, argenx SE's own PB Ratio has ranged from 3.02 to 10.43 over the past decade. While the company's 10-year median is 6.42 vs. the industry median of 2.80, argenx SE has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.80, based on 1,232 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. argenx SE's current PB Ratio of 7.49 is 167.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on argenx SE and its competitors. For the Biotechnology industry, the median PB Ratio is 2.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. argenx SE's current PB Ratio is 7.49, which is 17% above median its own 10-year median of 6.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is argenx SE stock overvalued right now?
Based on GuruFocus' analysis, argenx SE (ARGX) is currently considered Significantly Undervalued. The stock's GF Value™ is $1,363.68, compared to a current price of $885.80 — trading 35% below its estimated fair value. The current PB Ratio is 7.49, which is 17% above median its 10-year median of 6.42 and 167.5% above the Biotechnology industry median of 2.80. argenx SE's overall GF Score™ is 80/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For argenx SE (ARGX), the current PB Ratio is 7.49 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is argenx SE (ARGX) Overvalued in 2026?
Based on GuruFocus' analysis, argenx SE stock appears to be undervalued.
The current stock price of $885.80 is trading 35% below its estimated GF Value™ of $1,363.68.
GuruFocus considers argenx SE to be Significantly Undervalued.
Key valuation signals for ARGX:
PB Ratio: 7.49 (17% above median its 10-year median of 6.42)
GF Value™: $1,363.68 vs. price of $885.80 (35% below fair value)
Industry Position: 167.5% above the Biotechnology median (#1009 of 1232)
No single metric tells the full story. See the ARGX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
80GF Score
Get the complete analysis for ARGX
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ARGX has been successfully added to your 
